The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR therapy and ongoing investigations with the alfapump® system in Europe.

Social Life

Patients suffering from ascites report feelings of isolation and depression because of their immobility and limitations in their daily activities. It also entails a huge burden for their family members because of the frequent hospital visits for paracentesis and the feeling of being housebound and constant worrying when not around.

Although the alfapump® does not treat the underlying condition, patients who have been implanted with an alfapump® very often experience a significant improvement to their social life usually associated to their overall quality of life.

Many patients have been able to resume some of the light activities they enjoyed before suffering from ascites, such as swimming or taking a short walk. And many patients have reported an increase in appetite, enabling them to improve their nutrition, which is often critical in helping to manage their underlying disease.